Christopher D. Earl Resigning as CEO
Board member Melinda Moree named interim leader
WASHINGTON, June 25 /PRNewswire-USNewswire/ -- BIO Ventures for Global Health (BVGH) today announced that Christopher D. Earl, Ph.D., will resign from BVGH, effective July 9, 2009. Melinda Moree, Ph.D., a member of the board since BVGH's inception, will serve as interim CEO until a permanent replacement is hired.
"I've been galvanized by my experience in global health and honored to have the opportunity to contribute," says Dr. Earl. "I look forward to continuing to work at the interface of public health, science, and entrepreneurship."
"Chris's imagination and expertise have enabled BVGH to demonstrate the integral role the biotechnology industry can play in addressing the urgent medical needs of developing countries," says Robert B. Chess, Chairman of BVGH. "From promoting new financial incentives that reward companies for investing in global health R&D, to creating Innovation Maps that define a path toward making new breakthrough therapies, we thank Chris for his commitment and contributions. In particular, we are pleased that BVGH secured a three-year, $7 million renewal of funding from the Bill & Melinda Gates Foundation under Chris' leadership."
Melinda Moree, Ph.D., previously served as Executive Director for the PATH Malaria Vaccine Initiative, a $50 million/year Product Development Partnership funded by the Bill & Melinda Gates Foundation. She also served as Vice President, Global Health Services, Applied Strategies, supporting global, regional, and national health organizations in their mission to improve human health worldwide.
"BVGH has had an impact through initiatives launched by Chris such as last year's Partnering for Global Health Forum that brought together biotechnology executives and global health innovators," says Jim Greenwood, Presiden
|SOURCE BIO Ventures for Global Health|
Copyright©2009 PR Newswire.
All rights reserved